Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial

Conclusions</div>In resected stage I NSCLC patients adjuvant 400  mg/day pazopanib but not 800 mg/day was feasible, although possibly infra-therapeutic and failed to improve relapse-free survival.</span>
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research